Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

키워드

참고문헌 (13)

1. Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
2. Kim GA, "Critical appraisal of metabolic dysfunction-associated steatotic liver disease : Implication of Janus-faced modernity", Clin Mol Hepatol, 29, pp.831~843 (2023)
3. Younossi ZM, "Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease", J Hepatol, 80, pp.694~701 (2024)
4. Le MH, "Global incidence of adverse clinical events in non-alcoholic fatty liver disease : A systematic review and meta-analysis", Clin Mol Hepatol, 30, pp.235~246 (2024)
5. Agustanti N, "The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease : A systematic review and meta-analysis", Diabetes Metab Syndr, 17, pp.102780~ (2023)
6. Mantovani A, "Non-alcoholic fatty liver disease and risk of incident chronic kidney disease : an updated metaanalysis", Gut, 71, pp.156~162 (2022)
7. Chan KE, "Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease : A meta-analysis of 129studies", Clin Gastroenterol Hepatol, 22, pp.488~498 (2024)
8. Gao J, "Severity and remission of metabolic dysfunction-associated fatty", steatotic liver disease with chronic kidney disease occurrence, 2024, pp.13, e032604~
9. Tsutsumi T, "MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD : Generalized estimating equation approach", Hepatol Res, 51, pp.1115~1128 (2021)
10. Suzuki H, "Changing from NAFLD to MASLD : Similar prognosis of patients with HCC under atezolizumab", bevacizumab treatment between NAFLD and MASLD, 2024, pp.30, 263~265
11. Suzuki H, "Changing from NAFLD to MASLD : Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD", J Hepatol, 80, pp.e150~e151 (2024)
12. Suzuki H, "Changing from NAFLD to MASLD : Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia", Clin Mol Hepatol, 30, pp.577~579 (2024)
13. Fan X, "Systemic metabolic abnormalities : Key drivers of complications and mortality in MASLD", J Hepatol, 80, pp.e246~e248 (2024)

관련 논문AI추천